Founded in 2011, thanks to Wuhan Optics Valley Biological City and the continuous improvement of the regulatory system, Zhizhong has built a medical device technology transformation platform (CRO + CDMO) with "compliance and risk control" as the core, and has built a team based on "technical talents". Up to now, the team has nearly 200 people, including more than 30 graduate students and above. It has been successively recognized and invested by well-known investment institutions such as Qingkong Ginkgo (formerly Tsinghua Enlightenment), Zheshang Venture Capital, Optics Valley Investment and Baiying Fund. Based on "Wuhan and Hangzhou", it has branches in Beijing, Suzhou, Shanghai, Shenzhen and Guangzhou, providing integrated solutions such as "clinical trials, technical regulations, inspection and testing, CDMO, IP incubation".
Medical device system consultation, regulatory registration, clinical trials, inspection and testing, commissioned R & D, commissioned production, IP incubation.